VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MM 2018 | Opinion: value of MRD as an endpoint in hem-onc clinical trials

Measurable residual disease (MRD) is a hot topic, with it’s full potential still to be fully realized. We spoke to Robert Hills from the University of Oxford, Oxford, UK, about his thoughts on the value of MRD as an endpoint in clinical trials in the hemato-oncology field. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter